Latest Ratios: P/E Ratio -8.9x · EV/EBITDA N/A · ROE N/A. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $74M | $66M | $65M | $35M | $73M | $177M | $366M | $382M | $425M | $607M | — |
| Enterprise Value | $66M | $58M | $62M | $21M | $44M | $139M | $261M | $350M | $421M | $579M | — |
| P/E Ratio → | -8.95 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 54.40 | 130.85 | 2032.27 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 8.45 | 3.98 | 12.27 | — | 21.64 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 32.61 | 102.68 | 1447.69 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | — | — | — | — | -2756.4% | -4903.0% | -35672.8% | — | — | — | — |
| Net Profit Margin | — | — | — | — | -2463.3% | -4750.5% | -33873.9% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -371.5% | -113.8% | -99.2% | -350.2% | -588.3% | -455.0% | -109.4% |
| ROA | -26.5% | -26.5% | -37.6% | -59.2% | -52.1% | -64.6% | -75.5% | -147.6% | -275.1% | -384.5% | -92.8% |
| ROIC | — | — | — | — | — | — | — | — | — | -10673.3% | — |
| ROCE | -50.2% | -50.2% | -43.6% | -54.1% | -70.7% | -78.0% | -93.2% | -320.9% | -617.0% | -485.8% | -112.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.17 | 0.05 | 0.13 | — | — | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -1.82 | -1.15 | -1.03 | — | -0.98 | -0.93 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -2123.53 | -741.97 | -749.84 | -194.79 | — | — | -69.88 |
Net cash position: cash ($8M) exceeds total debt ($320000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | 1.54 | 2.60 | 2.31 | 5.24 | 4.96 | 8.24 | 4.06 | 0.36 | 6.75 | 5.64 |
| Quick Ratio | 1.54 | 1.54 | 2.60 | 2.31 | 5.24 | 4.96 | 8.24 | 4.06 | 0.28 | 6.75 | 5.33 |
| Cash Ratio | 0.93 | 0.93 | 0.27 | 1.93 | 5.07 | 4.78 | 7.96 | 3.57 | 0.24 | 6.38 | 4.48 |
| Asset Turnover | — | — | — | — | 0.03 | 0.02 | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | 0.04 | — | 0.02 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $40M | $40M | $39M | $39M | $39M | $30M | $25M | $23M | $21M | $17M |
Imminent liquidity and insolvency
As indicated by the negative TTM P/E of -8.35, BeyondSpring's valuation is currently untethered from traditional earnings metrics, reflecting a market that prices the equity as a distressed binary option rather than a viable commercial enterprise following the failure to secure FDA approval for its lead asset.
The absence of meaningful P/S or EV/EBITDA multiples underscores the market's inability to assign value to a pre-revenue pipeline that has faced significant regulatory setbacks. Investors appear to be discounting the company's future potential to near-zero, suggesting that any valuation recovery is entirely contingent on a successful pivot or a breakthrough in the Seed Therapeutics platform.
Based on 2026Q1 data, the company's current ratio has compressed to 1.09, a sharp decline from the 2.60 observed in 2024Q4, signaling that the firm's ability to cover short-term obligations is rapidly deteriorating as cash reserves are exhausted by ongoing clinical and operational expenses.
The convergence of the current and quick ratios at 1.09 suggests that the company is almost entirely dependent on its remaining cash to satisfy liabilities, leaving virtually no margin for error. This liquidity profile warrants extreme caution, as it indicates that the firm may be forced into highly dilutive financing or asset liquidation to maintain operations.
According to recent financial statements, the company's asset turnover has remained negligible, hovering near 0.02 in recent quarters, which confirms that the firm's capital base is not currently being utilized to generate productive revenue, but rather to sustain a high-burn research and development infrastructure.
The lack of meaningful asset turnover highlights the fundamental disconnect between the company's capital allocation and its commercial output. Without a product to market, traditional efficiency metrics like the cash conversion cycle are effectively irrelevant, serving only to emphasize the firm's status as a capital-consuming entity.
Investors frequently misapply standard P/E or EV/EBITDA multiples to BeyondSpring, which obscures the reality that the company is a pre-revenue clinical-stage entity where traditional valuation ratios are mathematically meaningless and fail to capture the underlying risk of regulatory failure or liquidity insolvency.
Instead of relying on earnings-based multiples, analysts should focus on the 'Cash Runway Ratio' and the 'Sum-of-the-Parts' valuation of the Seed Therapeutics platform. Using traditional valuation metrics on a company with no revenue and a negative equity position provides a false sense of precision that ignores the existential risks inherent in the current business model.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BYSI stock.
BeyondSpring Inc.'s current P/E ratio is -8.9x. This places it at the 50th percentile of its historical range.
Based on historical data, BeyondSpring Inc. is trading at a P/E of -8.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.